Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Hurst

Showing results (311-320 of 320) with videos related to

Pageof 32
Sort By:
You have reached the last page of results.This site can display upto 320 results.
Neurology|November 11, 2018
Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitisKevin Messacar, Stefan Sillau, Sarah E Hopkins, et al.
Cell|October 27, 2015
Engineering a therapeutic lectin by uncoupling mitogenicity from antiviral activityMichael D Swanson, Daniel M Boudreaux, Loïc Salmon, et al.
Biorxiv : the Preprint Server for Biology|November 3, 2020
A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cellsDrake M Mellott, Chien-Te Tseng, Aleksandra Drelich, et al.
Nature Communications|April 8, 2022
Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19Hengrui Liu, Sho Iketani, Arie Zask, et al.
Nature Communications|March 28, 2023
Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2Brian C Sanders, Suman Pokhrel, Audrey D Labbe, et al.
Nature Medicine|August 18, 2022
Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2Rachel J Hagey, Menashe Elazar, Edward A Pham, et al.
ACS Chemical Biology|March 31, 2021
A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey CellsDrake M Mellott, Chien-Te Tseng, Aleksandra Drelich, et al.
Science (New York, N.Y.)|November 2, 2021
An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19Dafydd R Owen, Charlotte M N Allerton, Annaliesa S Anderson, et al.
Journal of Medicinal Chemistry|April 30, 2024
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19Charlotte M N Allerton, Joel T Arcari, Lisa M Aschenbrenner, et al.
Journal of Medicinal Chemistry|February 28, 2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main ProteaseJamison B Tuttle, Christophe Allais, Charlotte M N Allerton, et al.
Pageof 32

Showing results (311-320 of 320) with videos related to

Sort By:
Pageof 32
You have reached the last page of results.This site can display upto 320 results.
Neurology|November 11, 2018
Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitisKevin Messacar, Stefan Sillau, Sarah E Hopkins, et al.
Cell|October 27, 2015
Engineering a therapeutic lectin by uncoupling mitogenicity from antiviral activityMichael D Swanson, Daniel M Boudreaux, Loïc Salmon, et al.
Biorxiv : the Preprint Server for Biology|November 3, 2020
A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cellsDrake M Mellott, Chien-Te Tseng, Aleksandra Drelich, et al.
Nature Communications|April 8, 2022
Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19Hengrui Liu, Sho Iketani, Arie Zask, et al.
Nature Communications|March 28, 2023
Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2Brian C Sanders, Suman Pokhrel, Audrey D Labbe, et al.
Nature Medicine|August 18, 2022
Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2Rachel J Hagey, Menashe Elazar, Edward A Pham, et al.
ACS Chemical Biology|March 31, 2021
A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey CellsDrake M Mellott, Chien-Te Tseng, Aleksandra Drelich, et al.
Science (New York, N.Y.)|November 2, 2021
An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19Dafydd R Owen, Charlotte M N Allerton, Annaliesa S Anderson, et al.
Journal of Medicinal Chemistry|April 30, 2024
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19Charlotte M N Allerton, Joel T Arcari, Lisa M Aschenbrenner, et al.
Journal of Medicinal Chemistry|February 28, 2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main ProteaseJamison B Tuttle, Christophe Allais, Charlotte M N Allerton, et al.
Pageof 32